Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 201 - 220 ( 441 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 - Will the Data at SITC and ASH Address NK Cell Duration?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Strategies and Therapeutic Opportunities to Address Checkpoint (IO) Resistance
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financials; Fate''s Many Threads to Come Together in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update; Burgeoning Pipeline Promises a Data Rich Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Five Drugs Crossed the IND Hurdle. Which One to Have the Best Fate?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Full Measure to Address Host Rejection
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Updates Show Continued Clinical Execution, Technological Advancement
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FT819 IND Clearance Ushers in a Broad Escalation and Expansion Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
For iPSC-Derived NK Cells, the Time Is Nigh With 4Q20 Poised to Provide Platform Validation; Initiating With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D